circLIFR acts as a tumor suppressor in HCC by regulating miR-624-5p and inactivating the GSK-3beta/beta-catenin signaling pathway.
CircLIFR suppresses hepatocellular carcinoma progression by sponging miR-624-5p and inactivating the GSK-3beta/beta-catenin signaling pathway.